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Major advances have recently been made in our under-
standing of the genetic basis of monogenic inherited
epilepsies. Progress has been particularly spectacular
with respect to idiopathic epilepsies, with the discovery
that mutations in ion channel subunits are implicated.
However, important advances have also been made in
many inherited symptomatic epilepsies, for which direct
molecular diagnosis is now possible, simplifying previ-
ously complex investigations. It is expected that identi-
fication of the genes implicated in familial forms of
epilepsies will lead to a better understanding of the
underlying pathophysiological mechanisms of these dis-
orders and to the development of experimental models
and new therapeutic strategies. In this article, we review
the clinical and genetic data concerning most of the
inherited human epilepsies.
pilepsies are frequent heterogeneous disor-
ders
1 and are caused by many factors.
2The contribution
of genetic and environmental factors varies among
epileptic disorders.Genetic factors are generally thought
to contribute to the etiology of 40% to 60% of human
epilepsies.
2,3 Inherited epilepsies are usually classified
according to whether the mode of inheritance is com-
plex or monogenic.In epilepsies with a complex mode of
inheritance, epilepsy results from the interaction
between environmental factors and genetic susceptibil-
ity, whereas in monogenic epilepsies, the genetic com-
ponent is prevalent,although environmental factors may
contribute to phenotypic expression and could explain
incomplete penetrance or variable clinical expression.
Finally, in epilepsies caused by exogenous factors (the
least genetically determined of the epilepsies), genetic
susceptibility could explain why only some of the indi-
viduals exposed to the same factors later develop
epilepsy.
Genetic studies in epilepsies are difficult to perform for
several reasons. First, most epilepsies have a complex
mode of inheritance and it is difficult to identify the
genes involved.Nonparametric analyses in a large num-
ber of affected individuals (ie,hundreds) are necessary.
However, difficulties are also encountered in genetic
studies of monogenic epilepsies,particularly in the iden-
tification of large informative families with enough
affected members to be useful for linkage analysis.Sec-
ond,phenotype analysis can be problematic.The clinical
status (ie,affected or not) of each member of the family
must be determined.This involves a choice of more or
less stringent electroclinical criteria to confirm the pres-
ence of the disease. The collection of reliable medical
information may be difficult, especially in the first gen-
eration of affected families. Moreover, the presence of
phenocopies (which are frequent for epilepsy and febrile
convulsions) and possible intrafamilial phenotypic het-
erogeneity must be taken into account.
Despite these difficulties, major advances have been
made in the genetics of epilepsy in the past 10 years.
Nearly all concern epilepsies with a monogenic mode
of inheritance,the least frequent of the inherited epilep-
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Pharmacological aspectssies.The progress in idiopathic epilepsies has been spec-
tacular, with the discovery that some of them may
involve mutations in ion channels, leading to the con-
cept of “channelopathies.”However,important advances
have also been made in symptomatic epilepsies,with the
discovery, for example, of genes implicated in neuronal
migration and various metabolic pathways.
It is expected that elucidation of the genetic basis of
monogenic epilepsy will also help us understand the
genetic basis of epilepsies with complex inheritance.
In this article,we review recent advances in the genetics
of epilepsy,focusing on the molecular and pathophysio-
logical aspects of some inherited epilepsies.
Idiopathic epileptic syndromes
It has long been suspected that genetic factors are preva-
lent in the etiology of idiopathic epilepsies. Most are
characterized by a complex inheritance—idiopathic
epilepsies with monogenic inheritance are rare. Those
in which a locus or genes have been identified are listed
in Table I.
4-46 For some of these,voltage- or ligand-gated
ion channels are implicated.
Idiopathic epileptic syndromes with monogenic 
inheritance: the new concept of channelopathies
To date, three familial idiopathic syndromes have been
found to be mediated by mutations in voltage- or lig-
and-gated ion channels.
Autosomal dominant nocturnal frontal lobe epilepsy
The syndrome of autosomal dominant nocturnal frontal
lobe epilepsy (ADNFLE) was first described by Scheffer
in 1994.
47,48 It is characterized clinically by the onset in
infancy of frequent brief partial seizures occurring in
clusters during sleep. Adult onset is less common. The
motor component of seizures predominates (paroxys-
mal dystonic postures, thrashing, ambulation). Some-
times, the symptoms are limited to sudden awakening.
Vocalizations or aura may precede the motor manifes-
tations.Misdiagnoses are frequent,especially confusion
with parasomnias (night terrors, somnambulism).
Seizures usually persist in adults,but tend to be less fre-
quent and respond to carbamazepine.Intrafamilial vari-
ations in severity are sometimes observed. Neuroimag-
ing is normal. When ictal electroencephalography
(EEG) recordings are interpretable,they show unilateral
or bilateral frontal/temporal epileptic activity.
Familial studies of this rare new syndrome demonstrated
autosomal dominant transmission with incomplete pen-
etrance. One locus was found in the region 20q13.2 by
linkage analysis in a large Australian pedigree.
4 The
CHRNA4 gene encoding for the alpha-4 subunit of the
neuronal nicotinic acetylcholine receptor (nAChR),
which has already been found in this genomic region,
was a good candidate. Indeed, subsequent screening of
the CHRNA4 gene in the first ADNFLE Australian fam-
ily described led to identification of a mutation in this
gene.
5 Other mutations of the CHRNA4 gene were sub-
sequently detected in several families.
6-8
nAChR receptors are heteropentameric ligand-gated
ion channels. The genes for eight human nAChR sub-
units have been mapped. The alpha-4 subunit is
expressed in all layers of the frontal cortex.The second
transmembrane domain of the alpha-4 subunit is cru-
cial to the permeability of the ion channel. Mutations
of the alpha-4 subunit are thought to decrease the activ-
ity of nAChR by reducing its affinity for acetylcholine
and permeability to calcium.
49,50 Neuronal nicotinic
receptors are thought to be almost exclusively presy-
naptic,regulating the release of neurotransmitters such
as glutamate. However, the mechanism by which
hypoactive nAChRs cause this partial familial epilepsy is
unknown.
Another ADNFLE locus has been found in the region
15q24 in one family.
9 Although this region is close to a
cluster of genes encoding other nAChR subunits
(CHRNA3, CHRNA5, and CHRNB4), mutations have
not been found in these subunits,and the causative gene
remains to be identified.
A third locus was recently identified in the pericen-
tromeric region of chromosome 1,
10 with the subsequent
identification of mutations in the beta-2 subunit of
nAChR (CHRNB2).
11,12 However,most ADNFLE fami-
lies are not linked to CHRNB2 or CHRNA4.
51
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Selected abbreviations and acronyms
ADNFLE autosomal dominant nocturnal 
frontal lobe epilepsy
BFNC benign familial neonatal convulsions
GEFS+ generalized epilepsy with febrile seizures–plus
nAChR nicotinic acetylcholine receptor 
PME progressive myoclonus epilepsy49
Benign familial neonatal convulsions
The syndrome known as benign familial neonatal con-
vulsions (BFNC) is characterized by the occurrence of
unilateral or bilateral clonic, apneic, or even tonic
seizures on the second or third day of life of a normal
neonate.Interictal EEGs rarely show what is described
as a “sharp alternating theta.”The outcome is generally
favorable, although some patients will develop febrile
seizures or nonfebrile seizures later in life.This familial
syndrome differs in several respects from the sporadic
form (benign neonatal convulsions), in which tonic
seizures are never observed, the typical interictal EEG
feature of a “sharp alternating theta” is more frequent,
and outcome is more favorable.
BFNC was the first idiopathic epilepsy in which genetic
linkage was established,
25 first to the q arm of chromo-
some 20,
25,26 and then to the q arm of chromosome 8.
30
Mutations in novel voltage-gated potassium channel
genes KCNQ2 (region 20q)
27-29 and KCNQ3 (region 8q)
31
Genetic aspects of epilepsies - Gourfinkel-An et al Dialogues in Clinical Neuroscience - Vol 3 . No.1 . 2001
Disorder Mode of inheritance Chromosomal region, gene/protein
Partial idiopathic epilepsies
  Autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) AD   20q, CHRNA4
4-8
15q, gene?
9
1 (pericentromeric region),
CHRNB2
10-12
  Familial lateral temporal epilepsy with auditory symptoms AD   10q, gene?
13-15
  Familial mesiotemporal epilepsy AD   Locus?
16,17
  Autosomal dominant partial epilepsy with variable foci AD   2qter, gene?
18
22q, gene?
19
  Benign familial infantile convulsions (BFIC)  AD   19q, gene?
20
Other locus?
  Infantile convulsions with paroxysmal choreoathetosis (ICCA)  AD   16p, gene?
21,22
  Familial rolandic epilepsy with paroxysmal  AR   16p, gene (only one family 
exercise-induced dystonia and writer’s cramp published)
23
  Familial rolandic epilepsy with speech dyspraxia  AD with anticipation   Locus? Expansion of 
and mental retardation trinucleotidic repeat is suspected 
(only one family published)
24
Generalized idiopathic epilepsies
  Benign familial neonatal convulsions (BFNC) AD   20q, EBN1, KCNQ2
25-29
8q, EBN2, KCNQ3
30,31
Third locus?
  Familial cortical tremor  AD   8q23.3-q24.1, gene?
32-34
(or benign adult familial myoclonic epilepsy) Other locus?
Familial febrile convulsions Variable mode    8q13-q21, FEB1, gene?
35
of inheritance
a 19p13.3, FEB2, gene?
36-38
11q, gene?
39
5q14-q15, FEB4, gene?
40
Generalized epilepsy with febrile seizures–plus (GEFS+) AD   19q13.1, SCN1B
41
2q21-q33, SCN1A
42-46
Third locus?
Table I. Genetics of idiopathic epilepsies with a monogenic mode of inheritance. AD, autosomal dominant; AR, autosomal recessive.
aSeveral modes of inheritance have been described for familial febrile convulsions: polygenic inheritance seems to be prevalent; however, 
autosomal dominant transmission with incomplete penetrance or autosomal recessive transmission have been described for some families. 50
were found in this familial syndrome, but the existence
of one or more loci is suspected.Most families are linked
to KCNQ2.
31 Only one KCNQ3-linked family has been
published to date.KCNQ2 and KCNQ3 are heteromeric
channels with highly homologous sequences. They are
predominantly expressed in all regions of brain and are
functionally associated, contributing to the M current
that regulates excitability of many neurons.
28,52 As
demonstrated by in vitro studies, the identified muta-
tions cause a minor loss of function of the channels.
28,29,53
The age-dependence of this familial syndrome may
result from difference in the cerebral expression of the
potassium channel genes over time.
54 Interestingly,muta-
tions in KCNQ1, a voltage-gated potassium channel
gene that is expressed in the heart and ear and is homol-
ogous to KCNQ2 and KCNQ3,cause two other familial
syndromes: the long-QT syndrome and Jervell-Lange-
Nielsen cardioauditory syndrome.
55,56
Generalized epilepsy with febrile 
seizures–plus syndrome
Febrile seizures are frequent events, the genetic com-
ponent of which is important. In some families, febrile
seizures are associated with nonfebrile seizures, consti-
tuting the syndrome described in 1997 as generalized
epilepsy with febrile seizures–plus (GEFS+).
57 In this
heterogeneous familial phenotype,some affected mem-
bers often have multiple febrile seizures that persist
beyond the age of 6, whereas other family members
have classic febrile seizures that disappear before the
age of 6.Variable nonfebrile seizures are also observed.
Initially, generalized seizures (tonic-clonic, myoclonic,
atonic,and absence seizures) were described,
57 but hemi-
convulsive, temporal, or frontal seizures were later
observed in other families.
42-44,58 These afebrile seizures
may begin in childhood in association with febrile
seizures, after a seizure-free period, or later in life. Fur-
thermore,not all affected members have febrile seizures.
Several types of seizure can coexist in a given patient
with electroclinical features that are more or less typical
of generalized idiopathic epilepsies or myoclonic astatic
epilepsy (Doose syndrome),but electroclinical patterns
that do not correspond to the international classifica-
tion of epilepsies are also observed.
59 Some patients are
intellectually disabled.
42 Outcome and response to treat-
ment are very variable within the same family. When
available,neuroimaging is normal.
GEFS+ is transmitted as an autosomal dominant trait
with incomplete penetrance, and is genetically hetero-
geneous.The first locus was found in the region 19q13.1,
and a mutation in the SCN1B gene coding for the beta 1 
subunit of the neuronal voltage-gated sodium chan-
nel was found in one family.
36A second locus in region
2q21-q33 seems to be more frequently implicated,
according to published reports in several families.
42-45 In
two French families, two different mutations were
identified in the SCN1A gene, which encodes for the
alpha-1 subunit of the same voltage-gated sodium
channel.
46 Functional studies in Xenopus oocytes have
demonstrated that mutations in the beta-1 and alpha-
1 subunits interfere with the functional properties of
the sodium channel.
A third locus is suspected because some GEFS+ families
are not linked to SCN1A or SCN1B.
36,46
Idiopathic epilepsies with 
complex inheritance
Most idiopathic generalized epilepsies (including juve-
nile myoclonic epilepsy,juvenile absence epilepsy,child-
hood absence epilepsy, and epilepsy with tonic-clonic
seizures on awakening) have a complex mode of inher-
itance.These diseases result from an interaction between
genetic susceptibility (often mediated by several genes)
and environmental factors.Linkage to the q arm of chro-
mosome 8,
60,61 and the p arms of chromosomes 1
62 and 3
63
have been reported for generalized epilepsies. Because
confirmatory reports in additional families have not
been forthcoming, these results should be considered
with caution.
Juvenile myoclonic epilepsy has been studied most
extensively,with controversial findings concerning link-
age to the regions 6p
64-69 and 15q14.
70
Most febrile seizures and benign rolandic epilepsy are
also thought to have complex modes of inheritance.
Linkage to the q arm of chromosome 15 was suggested
for benign rolandic epilepsy in one study.
71
Inherited developmental 
cortical malformations 
(neuronal migration disorders)
These developmental disorders are an important cause
of pharmacoresistant epilepsy,which is often associated
with mental retardation.
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Lissencephaly and double cortex syndrome
Lissencephaly is a rare disorder characterized by a
reduced number of cerebral gyri due to an arrest of neu-
ronal migration at 8 to 14 weeks of gestation.
72The cor-
tex is abnormally thick and the surface of the brain is
smooth. Microscopically, the cortex is poorly organized
with four to six primitive layers and diffuse neuronal
heterotopia.Affected children have severe mental retar-
dation,and often pharmacoresistant epilepsy and other
neurological abnormalities. Various types of seizures
(tonic-clonic,myoclonic,and tonic seizures,and infantile
spasms) occur early in life. Lissencephaly can be iso-
lated, as in isolated lissencephaly sequence or in hem-
izygous males affected with X-linked lissencephaly.
However, in Miller-Dieker syndrome, lissencephaly is
associated with facial dysmorphism.
In Miller-Dieker syndrome, and in around a third of
patients with isolated lissencephaly sequence, a het-
erozygous deletion or mutation has been demonstrated in
the LIS1 gene, which is located in the region 17p13.3.
73-75
The LIS1 gene is ubiquitously expressed and encodes a
noncatalytic subunit of platelet activating factor (PAF)
acetylhydrolase,an enzyme that inactivates PAF.
In males affected with X-linked lissencephaly, an X-
linked dominant inherited disease, the gene involved is
DCX, which encodes doublecortin and is located in the
region Xq22.3-q23.
76,77 Interestingly,in females,the same
mutations in the DCX gene lead to another phenotype,
the double cortex syndrome,which is characterized by a
laminar cerebral heterotopia.
76,77 Affected women have
pharmacoresistant epilepsy, but are less mentally
retarded than affected males.
More recently, rare cases of double cortex syndrome
have been reported in men with mutations in the LIS1
or DCX genes.
78,79 The LIS1 and DCX gene products
interact and interfere with dynamic properties of micro-
tubules.The exact mechanism that underlies abnormal
neuronal migration has not been elucidated.
Familial periventricular heterotopia
Periventricular heterotopia is characterized by the lining
of the ventricular walls with nodules that consist of neu-
rons that did not migrate to the cortex during brain
development. X-linked periventricular heterotopia is
lethal to males during the embryonic period. Affected
females have epilepsy without mental retardation,asso-
ciated with persistent ductus arteriosus,coagulopathies,
and skeletal abnormalities.The causative gene is FLN1,
which is located in the region Xq28
80 and encodes fil-
amin 1,an actin-binding protein that interacts with other
proteins of cytoskeleton.
Progressive 
myoclonus epilepsies
Progressive myoclonus epilepsies (PMEs) are rare dis-
orders that have some clinical features in common, but
different etiologies and variable outcomes. A specific
diagnosis for some of these diseases has been possible
for a long time, on the basis of characteristic stigmata
detected by pathological investigation. Numerous
advances in genetics now permit direct molecular diag-
nosis in most cases. We will focus here on the genetic
bases of Unverricht-Lundborg disease and Lafora’s dis-
ease. Other PMEs with their corresponding loci and
genes are listed in Table II.
81-120
Unverricht-Lundborg disease
Unverricht-Lundborg disease is an autosomal reces-
sive PME classically with onset between 6 and 15 years
of age, a slow progression, rare, late, and mild mental
deterioration, and cerebellar ataxia.
121,122 However,
more dramatic outcomes have been described, often
precipitated by phenytoin prescription.
123 More recen-
tly, late-onset forms of the disease have been
reported.
124 Both the Baltic and Mediterranean forms
of the disease are caused by mutations in the cystatin
B gene located in the region 21q22.3.
125,126 Rare point
mutations and deletions in the coding region of the
gene
81-84 lead to a loss of function of cystatin B. More
frequently, expansion of a dodecamer (CCC CGC
CCC GCG)n repeat in the 5′ untranslated region of
the gene
85-88 decreases transcription. Normal alleles
contain two to three copies of the dodecamer,whereas
mutant alleles contain more than 30 repeats of the
dodecamer.Preliminary studies have not provided evi-
dence of a correlation between the size of the dode-
camer expansion and age at onset of the disease.
88
There are probably premutation states,since interme-
diate size alleles with 12 to 17 dodecamer repeats have
been detected in individuals with normal phenotype
who were able to transmit pathologic alleles to their
offspring.
86The presence of these two types of mutations varies
according to the geographic origin of affected families.
The Baltic form of the disease is generally caused by a
point mutation in one copy of the cystatin B gene and
expansion of the dodecamer in the other copy or,more
rarely, by point mutations in both copies of the gene.
The Mediterranean form of the disease,characterized by
frequent consanguinity, results from expansion of the
dodecamer on both copies of the cystatin B gene.
Cystatin B is a cystein-protease inhibitor that is thought
to protect against apoptosis,but the mechanism leading to
Unverricht-Lundborg disease remains to be elucidated.
Pharmacological aspects
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Disorder Mode of inheritance Locus, gene, protein
Unverricht-Lundborg disease  AR   21q, EMP1, cystatin B
81-88
Lafora’s disease AR    6q, EMP2A, laforin
89,90
Other locus? 
Neuronal ceroid lipofuscinoses
  Early infantile form, late infantile form,  AR   1p32, CLN1, lysosomal palmitoyl-
and variant of juvenile form, all with  protein thioesterase I
91-95
cytoplasmic granular osmiophilic deposits
  Classic late infantile form AR   11p15, CLN2, tripeptidyl 
peptidase I
96-98
  Variant of late infantile form AR   15q21-23, CLN6,
96 gene?
  Finnish late infantile form AR   13q21-32, CLN5, new protein 
of unknown function
99
  Turkish late infantile form
100 AR   Locus, CLN7? gene?
  Juvenile form AR   16p12 (CLN3), novel protein
involved in lysosomal pH 
regulation
101-103
  Adult form (Kufs’ disease)
104 AD   Locus (CLN4)? gene?
Myoclonus epilepsy and ragged-red fibers Maternal transmission   Mitochondrial genome
(MERRF) syndrome  8344 tRNA
Lys is the prevalent
mutation
105-107
Sialidoses AR   6p, α -neuraminidase
108,109
20q, stabilizing protein of the 
α -neuraminidase-β -
galactosidase complex
110
Juvenile form of Gaucher’s disease AR   1q, β -glucocerebrosidase
111,112
Juvenile form of GM2 gangliosidosis AR   15q23-24, β -hexosaminidase A 
α -subunit gene
113,114
Dentatorubral-pallidoluysian atrophy
a AD   12p, atrophin
115
Huntington’s disease
a AD   4q, huntingtin
116,117
Familial form of Alzheimer’s disease
a AD   14q, presenilin 1
118,119
Mutation in neuroserpin gene
a (one family published) AD   3q26, neuroserpin
120
Table II. Inherited progressive myoclonus epilepsies. AD, autosomal dominant; AR, autosomal recessive.
aProgressive myoclonic epilepsy may be a clinical form of the disease. Genetic aspects of epilepsies - Gourfinkel-An et al Dialogues in Clinical Neuroscience - Vol 3 . No.1 . 2001
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Lafora’s disease
Lafora’s disease is an autosomal recessive PME charac-
terized by onset between age 10 and 18, rapid neuro-
logical and cognitive decline, and fatal outcome after
about 10 years of progression. Focal occipital seizures
are frequent.
127 Until recently,diagnosis was established
by observation of intracellular polyglucosan inclusions
(Lafora bodies) on skin biopsies.
128 Direct molecular
diagnosis is now possible.
Linkage analysis and homozygosity mapping localized
the gene in the region 6q23-25.
129,130The gene,identified
by positional cloning,
89,90 encodes a protein tyrosine
phosphatase,laforin,which is a tyrosine kinase inhibitor.
Laforin is thought to be involved in glycogen metabo-
lism. Homozygous deletions and several homozygous
point mutations in the coding part of the gene have been
found in affected families.
89,90At least one other locus is
probably also responsible for Lafora disease.
131,132
Inherited neurologic disorders 
and chromosomal disorders
with epilepsy as 
a part of the phenotype
Epilepsy is observed among complex neurological or extra-
neurological symptoms in numerous chromosomal disor-
ders and inherited disorders affecting the central nervous
system. They cannot be described in detail in this review
and most are listed in Tables III and IV.
106,133-147The frequency
of epilepsy in these complex syndromes is variable.
Conclusion
Genetic studies of previously well-defined epileptic syn-
dromes have led to the identification of causative genes
in some cases,but also to the identification of new famil-
ial epileptic syndromes that are not yet included in the
international classification of epilepsies and epileptic
syndromes.
59 In the future,this classification will proba-
bly take into account these new familial epileptic disor-
ders with their particular electroclinical features and
prognoses.
The genetic heterogeneity of epilepsies is becoming
more and more apparent.Different genes,which may or
not be functionally linked,and different mutations may
cause the same familial epileptic syndrome.At the same
Disorder Mode of inheritance Locus, gene, protein
Tuberous sclerosis AD   9q34, TSC1, tuberin
133,134
16p13.3, TSC2, hamartin
133,135
Type 1 neurofibromatosis  AD   17q11.2, NF1, neurofibromin
136
Familial cerebral cavernomas AD   7q, KRIT1 gene
137-139
7p
3q
Rett’s syndrome Dominant X-linked   Xq28, MECP2 gene
140
Mitochondrial myopathy, encephalopathy, lactic Maternal transmission   Mitochondrial genome: 3243
acidosis and stroke-like episodes (MELAS) tRNA
Leu is the prevalent 
mutation
106,141
Fragile X syndrome Dominant X-linked
a   Xq27.3, FMR1 and FMR2 genes
142-144
Some types of gangliosidosis AR   Variable
145-147
Table III. Principal inherited disorders with epilepsy as a part of phenotype. AD, autosomal dominant; AR, autosomal recessive.
aWith unusual characteristics: the mutation can be passed through phenotypically normal males (normal male carriers) and their daughters are
almost never affected. In contrast, 30% of carrier females are mentally retarded.
  Trisomy 21 (Down’s syndrome)
  Angelman syndrome (partial monosomy 15q11)
  Trisomy 12p
  Wolf-Hirschhorn syndrome (partial monosomy 4p)
  Klinefelter’s syndrome (XXY)
  Ring chromosome 20
Table IV.  Principal chromosomal disorders associated with epilepsy.time, significant intrafamilial phenotypic heterogeneity
can often be observed. This is particularly clear in the
GEFS+ syndrome. One hypothesis is that the expres-
sion of the mutated genes differs among family mem-
bers, causing clinical heterogeneity. Alternatively, the
gene may intervene in epileptogenesis at a very general
level,affecting epileptic susceptibility or modulating the
epileptogenic threshold, and other genetic or environ-
mental factors may influence the electroclinical profile
of the disease in each affected subject.
There are many pathophysiological mechanisms under-
lying inherited epilepsies.The functional or morpholog-
ical consequences of the mutations that give rise to an
epileptic process are extremely variable.The discovery
of dysfunction of ion channels in several idiopathic
epilepsies has led to the concept of channelopathies,but
abnormal neuronal migration, premature neuronal
death,metabolic disturbances,and other anomalies may
also be involved.
Finally,progress in the genetics of human epilepsies has
had important consequences for clinical practice. Spe-
cific molecular diagnosis is now possible in symptomatic
individuals for several diseases,some of which have poor
prognoses.Predictive diagnosis in presymptomatic indi-
viduals is also possible, although it does pose ethical
problems. From a pharmacological point of view, these
recent genetic discoveries should help understand the
response (or resistance) of some epileptic syndromes to
treatment and the adverse effects sometimes observed
with antiepileptic drugs,and generate new antiepileptic
drugs.❑
We wish to thank Dr Merle Ruberg for critical reading of the manuscript.
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Genética de las epilepsias humanas 
heredadas
Recientemente se han logrado importantes avan-
ces en la comprensión de las bases genéticas de
las epilepsias monogénicas heredadas. El progre-
so ha sido particularmente espectacular en rela-
ción a las epilepsias idiopáticas, al descubrir que
están involucradas las mutaciones en subunidades
de los canales iónicos. Sin embargo, también se
han obtenido importantes avances en muchas
epilepsias sintomáticas heredadas, en las cuales el
diagnóstico molecular directo ahora es posible,
simplificando complejas investigaciones previas.
Se espera que la identificación de genes involu-
crados en formas familiares de epilepsias conduz-
ca a una mejor comprensión de los mecanismos
fisiopatológicos subyacentes de estos trastornos y
al desarrollo de modelos experimentales y nuevas
estrategias terapéuticas. En este artículo se revi-
san datos clínicos y genéticos que se relacionan a
la mayoría de las epilepsias humanas heredadas.
La génétique des épilepsies héréditaires
De grands progrès ont été récemment enregis-
trés dans la compréhension des bases génétiques
des épilepsies héréditaires monogéniques. Ces
progrès ont été particulièrement spectaculaires
dans le domaine des épilepsies idiopathiques
grâce à la découverte du rôle des mutations des
sous-unités des canaux ioniques. Des avancées
importantes ont par ailleurs également été réali-
sées en ce qui concerne de nombreuses épilepsies
symptomatiques héréditaires puisque leur dia-
gnostic moléculaire direct est maintenant pos-
sible, simplifiant ainsi les recherches complexes
autrefois nécessaires. L’identification des gènes
impliqués dans les formes familiales d’épilepsie
devrait permettre une meilleure compréhension
des mécanismes physiopathologiques sous-jacents
à ces troubles ainsi que le développement de
modèles expérimentaux et de nouvelles straté-
gies thérapeutiques. Dans cet article, nous pas-
sons en revue les données cliniques et génétiques
concernant la plupart des épilepsies héréditaires
humaines. Genetic aspects of epilepsies - Gourfinkel-An et al Dialogues in Clinical Neuroscience - Vol 3 . No.1 . 2001
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